IRVINE, Calif., May 16, 2005 (PRIMEZONE) -- SmallCap Sentinel announced today the availability of informational resources detailing developments by a biotech company that may offer major advancements in MRI safety for patients that receive the next generation of implanted medical devices such as neurostimulators and cardiac pacemakers. This comes on the heels of an FDA health advisory that points out serious safety risks associated with the use of Magnetic Resonance Imaging (MRI) procedures with patients that have implanted neurostimulators. The full advisory, which was widely reported in the media this week, can be viewed on the FDA's web site at http://www.fda.gov/cdrh/safety/neurostim.html.
"According to the FDA advisory, metal wire leads may act as antennas collecting energy generated by electromagnetic fields with MRI systems," said SmallCap Sentinel analyst D.R. Clark. "Energy picked up by the neurostimulator leads via an MRI machine's electromagnetic field, can cause the wire lead to heat up to generate induced voltages that can cause device malfunctions, leading to death or other complications. The FDA advisory indicated that there have been several reports of serious injury, including coma and permanent neurological impairment, in patients with implanted neurological stimulators who underwent MRI procedures. Using Biophan's anti-antenna technology and RF filter solution technology to modify the metal wire lead that connects the implantable device to tissue may significantly reduce problems of both heating and induced electrical voltages."
Biophan Technologies, Inc. (OTCBB:BIPH) has developed and demonstrated a number of proprietary technology solutions that are being offered to manufacturers under license for reducing MRI-induced heating of electrical wire leads used in many medical devices, including pacemakers and neurostimulators. The largest manufacturers of neurostimulators, Cyberonics, Inc. (Nasdaq:CYBX) and Medtronics, Inc. (NYSE:MDT), developed the devices to treat conditions such as chronic pain, epilepsy and Parkinson's disease. Biophan offers proprietary technology to enable manufacturers of such medical devices to create a new generation of devices that are safe for use with MRI systems.
Interested parties may view information about Biophan free of charge via this direct link: http://www.trilogy-capital.com/biph_summary.aspx
Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Company Web site: www.biophan.com.
Forward-Looking Statements
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Biophan Technologies, Inc. for preparation and distribution of this report and other advertising services. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.